Effects of Cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical-electrophysiological study)

被引：24

作者：

Damulin I.V. ^{[1
]}

Koberskaya N.N. ^{[1
]}

Mkhitaryan É.A. ^{[1
]}

机构：

[1] Department of Nervous Diseases, I. M. Sechenov Moscow Medical Academy, Moscow

来源：

Neuroscience and Behavioral Physiology | 2008年 / 38卷 / 6期

关键词：

300 cognitive evoked potentials; Cerebral vascular insufficiency; Cerebrolysin; Impairment of cognitive functions;

D O I：

10.1007/s11055-008-9014-5

中图分类号：

学科分类号：

摘要：

The efficacy of treatment with cerebrolysin was studied in 40 patients with cerebral vascular insufficiency. Cerebrolysin (20 daily i.v. infusions of 10 ml in 200 ml of physiological saline) was found to be an effective means of treating this group of patients. Courses of cerebrolysin treatment decreased the severity of memory and attention impairments, improving the overall cognitive status of the patients. Clinical observations and neuropsychological testing were supported by electrophysiological results, in terms of the P300 cognitive evoked potential. The effects of treatment at the doses used here were delayed and were seen three months after completion of treatment. © Springer Science+Business Media, Inc. 2008.

引用

页码：639 / 645

页数：6

共 41 条

[21]

Yakhno N.N., Damulin I.V., Zakharov V.V., Et al., Experience of the use of high doses of cerebrolysin in vascular dementia, Ter. Arkh., 68, 10, pp. 65-69, (1996)

[22]

Yakhno N.N., Levin O.S., Damulin I.V., Comparison of clinical and MRI data in cerebral vascular insufficiency. 2. Cognitive impairments, Nevrol. Zh., 6, 3, pp. 10-18, (2001)

[23]

Boado R.J., In vivo upregulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived peptides, Eur. J. Neurol., 6, SUPPL. 3, (1999)

[24]

Duma S., Mutz N., Wirsamkeit einer Peptid-Dextran-Kombination in der Behandlung von Schadel-Hirn-Verletzten, Neuropsychiatrie, 4, pp. 69-72, (1990)

[25]

Folstein M.F., Folstein S.E., McHugh P.R., 'Mini-mental state:' A practical method for grading the cognitive state of patients for the clinician, J. Psychiat. Res., 12, pp. 189-198, (1975)

[26]

Gauthier S., Results of a 6-month randomized placebo-controlled study with Cerebrolysin in Alzheimer's disease, Eur. J. Neurol., 6, SUPPL. 3, (1999)

[27]

Goodin D.S., Aminoff M.J., Electrophysiological differences between demented and nondemented patients with Parkinson's disease, Ann. Neurol., 21, pp. 90-94, (1987)

[28]

Jelasic F., Klinische Erfahrungen mit Cerebrolysin bei schweren hirnorganischen Prozessen, 52, pp. 1829-1831, (1976)

[29]

Koppi S., Barolin G.S., Hamodilutionstherapie mit nervenzellstoffwechsel-aktiver Therapie beim ischamischen Insult: Ermutigende Resultate einer Vergleichsstudie, Wien Med. Wochschr., 146, 3, pp. 41-48, (1996)

[30]

Linden D.E.J., The P300: Where in the brain is it produced and what does it tell us?, Neuroscientist, 11, pp. 563-576, (2005)

← 1 2 3 4 5 →